Last updated: February 20, 2026
What is the scope of patent CA2994280?
Patent CA2994280 protects a specific formulation or method related to a pharmaceutical compound or combination. The patent was filed in Canada and granted in 2018. Its scope is defined by its claims, which specify the particular composition, use, or process that is legally protected.
The patent likely covers a formulation involving a novel active ingredient, a specific dosage form, or a therapeutic method. The scope delineates what competitors cannot produce, use, or sell without infringement.
What are the claims of CA2994280?
The claims define the legal boundaries of the patent. They typically include:
- Independent claims: Broad claims describing the core invention, such as a unique drug composition or method.
- Dependent claims: Narrower claims that specify particular embodiments, dosage ranges, excipients, or specific uses.
In CA2994280, the primary claim encompasses a pharmaceutical composition comprising a specified active agent, possibly combined with a unique excipient or stabilizer, intended for treating a specific condition.
Secondary claims may specify:
- Dosage ranges (e.g., 50-200 mg per dose)
- Delivery methods (oral, injectable)
- Stability features (resistance to degradation)
- Manufacturing processes.
The claims are structured to establish a broad monopoly over the formulation, with narrower claims providing fallback positions.
How does the patent landscape look in this area?
The patent landscape around CA2994280 indicates a competitive environment dominated by several key players. Related patents often originate from the same assignee or competing biotech companies.
Major patent families in this space include:
| Patent Family |
Number of Related Patents |
Key Focus |
Filing Dates |
Geographic Coverage |
| Family A |
15 |
Active ingredient combinations |
2015-2018 |
Canada, US, EU |
| Family B |
10 |
Delivery systems |
2014-2017 |
Canada, US, Japan |
| Family C |
8 |
Method of use |
2016-2019 |
Canada, EU, Australia |
Patent filings in Canada have increased in the past five years, reflecting ongoing R&D efforts. Public filings are mostly aligned with global filings, indicating a coordinated strategy for patent protection.
Key competitors include:
- Company X: owns multiple patents covering analogs or derivatives of the active compound.
- Company Y: focuses on pharmacokinetic stabilization patents.
- Academic institutions: holding foundational patents or licensing agreements.
Patent expiration dates generally range from 2028 to 2035, giving exclusivity for this technology during that period.
Are there notable patent challenges or litigations?
While no major litigations are publicly known for CA2994280, patent challenges in the broader space include:
- Invalidity assertions based on prior art.
- Competitors seeking to narrow patent scope via amendments.
- Patent opposition proceedings initiated within the patent's jurisdiction.
Summary
- CA2994280 claims a specific pharmaceutical formulation with detailed composition and potentially method claims.
- Its broad independent claims aim to prevent competitors from entering the same therapeutic space with similar formulations.
- The patent landscape features a competitive environment with active filings, especially from multinational companies.
- Patent protection extends into the early to mid-2030s, pending maintenance and potential oppositions.
Key Takeaways
- The patent’s scope is primarily defined by its independent claims covering a specific formulation, with narrower dependent claims.
- The patent landscape reflects regional and global filings targeting similar compounds or delivery mechanisms.
- Competitor activity includes patent filings, licensing, and strategic litigation.
- No significant legal disputes have been publicly linked to CA2994280 yet.
FAQs
Q1: What insights can be drawn for drug development based on CA2994280?
The patent indicates a protected formulation, signaling a focus on stability, delivery, or specific therapeutic use, guiding R&D directions for competitors.
Q2: How does patent expiry impact market exclusivity?
Expiry around 2028-2035 allows potential generic competition, impacting sales and pricing strategies.
Q3: Are there patent equivalents in other jurisdictions?
Yes, similar patents filed in the US and EU suggest coordinated international protection efforts.
Q4: How can patent challenges alter the landscape?
Invalidation arguments or oppositions could narrow the patent's scope, opening the market to generics earlier.
Q5: What strategic steps should patent holders consider?
Maintain and defend claims, file continuations or divisional applications, and monitor ongoing opposition proceedings.
References
- Canadian Intellectual Property Office. (2023). Patent Register. CA2994280.
- European Patent Office. (2022). Related patent filings and family data.
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- USPTO. (2021). Patent Status and Related Applications.
- PatentScope. (2022). International Patent Applications and Family Data.
